293 related articles for article (PubMed ID: 32814730)
21. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
23. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
24. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract][Full Text] [Related]
25. Vandetanib for the treatment of medullary thyroid cancer.
Chau NG; Haddad RI
Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
[TBL] [Abstract][Full Text] [Related]
26. The evolving field of kinase inhibitors in thyroid cancer.
Marotta V; Sciammarella C; Vitale M; Colao A; Faggiano A
Crit Rev Oncol Hematol; 2015 Jan; 93(1):60-73. PubMed ID: 25240824
[TBL] [Abstract][Full Text] [Related]
27. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
Colombo C; De Leo S; Di Stefano M; Vannucchi G; Persani L; Fugazzola L
J Clin Endocrinol Metab; 2019 Mar; 104(3):779-784. PubMed ID: 30383218
[TBL] [Abstract][Full Text] [Related]
28. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
[TBL] [Abstract][Full Text] [Related]
29. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Toda S; Masudo K
Medicine (Baltimore); 2019 Oct; 98(42):e17588. PubMed ID: 31626129
[TBL] [Abstract][Full Text] [Related]
30. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.
Costa R; Carneiro BA; Chandra S; Pai SG; Chae YK; Kaplan JB; Garrett HB; Agulnik M; Kopp PA; Giles FJ
Drug Des Devel Ther; 2016; 10():873-84. PubMed ID: 27013865
[TBL] [Abstract][Full Text] [Related]
32. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
33. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
34. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
35. Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review.
Pham B; Kwon SM; Castillo DR; Majeed Y; Ahmad S; Hou J; Ganesan L; Mohammad S; Cao H
J Oncol Pharm Pract; 2022 Dec; 28(8):1930-1935. PubMed ID: 35369811
[TBL] [Abstract][Full Text] [Related]
36. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival.
De Leo S; Di Stefano M; Persani L; Fugazzola L; Colombo C
Endocrine; 2021 May; 72(2):462-469. PubMed ID: 32885329
[TBL] [Abstract][Full Text] [Related]
38. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
[TBL] [Abstract][Full Text] [Related]
39. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
